131 related articles for article (PubMed ID: 8961974)
1. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide.
Chen CL; Fuscoe JC; Liu Q; Pui CH; Mahmoud HH; Relling MV
J Natl Cancer Inst; 1996 Dec; 88(24):1840-7. PubMed ID: 8961974
[TBL] [Abstract][Full Text] [Related]
2. A human lymphoid leukemia cell line with a V(D)J recombinase-mediated deletion of hprt.
Chen CL; Woo MH; Neale GA; Goorha RM; Fuscoe JC; Behm FG; Mathew S; Relling MV
Mutat Res; 1998 Jul; 403(1-2):113-25. PubMed ID: 9726012
[TBL] [Abstract][Full Text] [Related]
3. Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells.
Chen CL; Fuscoe JC; Liu Q; Relling MV
Blood; 1996 Sep; 88(6):2210-8. PubMed ID: 8822941
[TBL] [Abstract][Full Text] [Related]
4. Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion.
Libura J; Slater DJ; Felix CA; Richardson C
Blood; 2005 Mar; 105(5):2124-31. PubMed ID: 15528316
[TBL] [Abstract][Full Text] [Related]
5. MLL rearrangements are induced by low doses of etoposide in human fetal hematopoietic stem cells.
Moneypenny CG; Shao J; Song Y; Gallagher EP
Carcinogenesis; 2006 Apr; 27(4):874-81. PubMed ID: 16377807
[TBL] [Abstract][Full Text] [Related]
6. Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines.
Liu WM; Oakley PR; Joel SP
Leukemia; 2002 Sep; 16(9):1705-12. PubMed ID: 12200685
[TBL] [Abstract][Full Text] [Related]
7. The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration.
Liu WM; Joel SP
Cancer Chemother Pharmacol; 2003 Apr; 51(4):291-6. PubMed ID: 12721756
[TBL] [Abstract][Full Text] [Related]
8. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy.
Karnaoukhova L; Moffat J; Martins H; Glickman B
Cancer Res; 1997 Oct; 57(19):4393-407. PubMed ID: 9331103
[TBL] [Abstract][Full Text] [Related]
9. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.
Kollmannsberger C; Beyer J; Droz JP; Harstrick A; Hartmann JT; Biron P; Fléchon A; Schöffski P; Kuczyk M; Schmoll HJ; Kanz L; Bokemeyer C
J Clin Oncol; 1998 Oct; 16(10):3386-91. PubMed ID: 9779717
[TBL] [Abstract][Full Text] [Related]
10. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note.
Kaufmann SH
Cancer Res; 1989 Nov; 49(21):5870-8. PubMed ID: 2790800
[TBL] [Abstract][Full Text] [Related]
11. Etoposide-induced DNA cleavage in human leukemia cells.
Edwards CM; Glisson BS; King CK; Smallwood-Kentro S; Ross WE
Cancer Chemother Pharmacol; 1987; 20(2):162-8. PubMed ID: 2822274
[TBL] [Abstract][Full Text] [Related]
12. Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis.
RamaChandran S; Ariffin H
Pediatr Blood Cancer; 2009 Sep; 53(3):488-90. PubMed ID: 19434733
[TBL] [Abstract][Full Text] [Related]
13. [Chromosome translocations and leukemias induced by inhibitors of topoisomerase II anticarcinogenic drugs].
Dassonneville L; Bailly C
Bull Cancer; 1998 Mar; 85(3):254-61. PubMed ID: 9752316
[TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerase II in therapy-related acute promyelocytic leukemia.
Mistry AR; Felix CA; Whitmarsh RJ; Mason A; Reiter A; Cassinat B; Parry A; Walz C; Wiemels JL; Segal MR; Adès L; Blair IA; Osheroff N; Peniket AJ; Lafage-Pochitaloff M; Cross NC; Chomienne C; Solomon E; Fenaux P; Grimwade D
N Engl J Med; 2005 Apr; 352(15):1529-38. PubMed ID: 15829534
[TBL] [Abstract][Full Text] [Related]
15. Role of apoptotic nuclease caspase-activated DNase in etoposide-induced treatment-related acute myelogenous leukemia.
Hars ES; Lyu YL; Lin CP; Liu LF
Cancer Res; 2006 Sep; 66(18):8975-9. PubMed ID: 16982737
[TBL] [Abstract][Full Text] [Related]
16. DNA damage induced by etoposide; a comparison of two different methods for determination of strand breaks in DNA.
Walles SA; Zhou R; Liliemark E
Cancer Lett; 1996 Aug; 105(2):153-9. PubMed ID: 8697438
[TBL] [Abstract][Full Text] [Related]
17. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
Dissing M; Le Beau MM; Pedersen-Bjergaard J
J Clin Oncol; 1998 May; 16(5):1890-6. PubMed ID: 9586906
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
19. The frequency of illegitimate V(D)J recombinase-mediated mutations in children treated with etoposide-containing antileukemic therapy.
Fuscoe JC; Knapp GW; Hanley NM; Setzer RW; Sandlund JT; Pui CH; Relling MV
Mutat Res; 1998 Nov; 419(1-3):107-21. PubMed ID: 9804912
[TBL] [Abstract][Full Text] [Related]
20. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins.
Pui CH; Relling MV; Behm FG; Hancock ML; Boyett JM; Raimondi SC; Krance RA; Mahmoud HH; Ribeiro RC; Sandlund JT
Leukemia; 1995 Oct; 9(10):1680-4. PubMed ID: 7564509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
